文献速递妇科

基于生物标志物值预测局部晚期宫颈癌预后的新评分

A new score based on biomarker values to predict the prognosis of locally advanced cervical cancer.
PubMed 文献 · Gynecol Oncol · 2020-08-19

本研究为前瞻性研究,纳入238例局部晚期宫颈癌患者,所有患者均接受放化疗和近距离放疗。基于治疗前血红蛋白<12 g/dL、白细胞>10,000/μL和血小板>300×10⁹/L三个指标构建评分(最高3分),评分2或3分者复发风险高。

要点

  • 基于血红蛋白<12 g/dL、白细胞>10,000/μL、血小板>300×10⁹/L构建评分,最高3分。
  • 评分2或3分者36个月无病生存率和总生存率较低。
  • 作者认为该评分可在诊断时识别高复发风险患者,这些患者需要剂量递增。

核心结论

  • 该评分包含三个生物标志物,切点易于记忆,可在诊断时识别高复发风险(评分2或3分)及需要剂量递增的患者。

研究设计与样本

  • 前瞻性研究,纳入238例局部晚期宫颈癌患者,所有患者PET成像显示腹主动脉旁区域阴性并接受腹腔镜腹主动脉旁淋巴结清扫术,均接受放化疗和近距离放疗。

主要发现

  • 患者临床FIGO分期为IB2期(n=76)、IIA期(n=13)、IIB期(n=122)、III期(n=18)或IVA期(n=9)。
  • 治疗前血红蛋白<12 g/dL、白细胞>10,000/μL和血小板>300×10⁹/L三个指标影响无病生存期和总生存期。
  • 评分0、1、2、3分对应的36个月无病生存率分别为87.3%[78.3-97.4]、58%[45-74.6]、79.1%[71.1-88]、58%[45-74.6]和56.8%[37.8-85.4](原文列出5个数值对应4个评分,原文此处表述存在矛盾)。
  • 评分0、1、2、3分对应的36个月总生存率分别为92.6%[84.9-100]、84%[76.6-92.1]、62.5%[48.9-79.9]和67%[46.8-96]。

关键数值与推荐

  • 血红蛋白<12 g/dL、白细胞>10,000/μL、血小板>300×10⁹/L三个指标各计1分,总分最高3分。
  • 评分2或3分者复发风险高。

临床怎么用

  • 作者认为该评分可在诊断时识别高复发风险(评分2或3分)患者,这些患者需要剂量递增。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To define a prognostic score based on pretreatment values of leucocyte, platelet and hemoglobin in locally advanced cervical cancer (LACC). MATERIAL AND METHODS: We conducted a prospective study of 238 patients for LACC with negative PET imaging in the para-aortic (PA) area and who were undergoing laparoscopic PA lymphadenectomies. All patients were treated with chemo-radiation and brachytherapy. RESULTS: Patients had clinical International Federation of Gynecology and Obstetrics stages IB2 (n = 76), IIA (n = 13), IIB (n = 122), III (n = 18) or IVA (n = 9). We identified three biological parameters (at the time of diagnosis) with three cut-offs which impacted disease free survival (DFS) and overall survival (OS): <12 g/dL for hemoglobin, >10,000/μL for leucocyte and >300 × 109/L for platelet. A score is calculated, as shown in the table below, by adding the scores of all three biological parameters together (with a maximum score of three). DFS at 36 months was 87.3% [78.3-97.4], 58% [45-74.6], 79.1% [71.1-88], 58% [45-74.6] and 56.8% [37.8-85.4] for scores of 0, 1, 2 and 3 respectively. OS at 36 months was 92.6% [84.9-100], 84% [76.6-92.1], 62.5% [48.9-79.9] and 67% [46.8-96] for scores of 0, 1, 2 and 3 respectively. CONCLUSION: This score includes three biomarkers with easily remembered cut-offs that allow us to identify, at the time of diagnosis, those patients with a high risk of relapse (scores of two or three) and those requiring dose escalation.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Maulard A, Chargari C, Faron M, et al. A new score based on biomarker values to predict the prognosis of locally advanced cervical cancer. Gynecol Oncol. 2020. PMID: 32828580. doi:10.1016/j.ygyno.2020.08.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。